Tiziana Completes INFORM-MS Phase 2a Trial of Intranasal Foralumab
BOSTON, Mass. — September 21, 2026 Tiziana Life Sciences announced that the last patient has completed the last visit...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON, Mass. — September 21, 2026 Tiziana Life Sciences announced that the last patient has completed the last visit...
BOSTON, July 31, 2026 Tiziana Life Sciences announced new quantitative PET imaging results from the third patient with Multiple...
Boston, MA, USA – April 1, 2026 In a promising development for age-related cognitive decline and neurodegenerative disorders, Tiziana...
